Please login to the form below

Not currently logged in
Email:
Password:

Nektar

This page shows the latest Nektar news and features for those working in and with pharma, biotech and healthcare.

Syncona launches another cell therapy company, Treg specialist Quell

Syncona launches another cell therapy company, Treg specialist Quell

Treg therapy developed by Nektar Therapeutics. ... Similarly, Lilly/Nektar’s NKTR-358 also targets the IL-2 receptor complex to stimulate Treg production.

Latest news

More from news
Approximately 7 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting topoisomerase I inhibitor for metastatic breast cancer (phase III). ‡‡

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics